文档介绍：Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA 2002;288:2981-2997
ALLHAT
： :// ；ndpoint = Fatal CHD or nonfatal MI
Chlorthalidone vs Lisinopril
Primary Endpoint
RR =
p =
Chlorthalidone
Lisinopril
All Cause Mortality
RR =
p =
ALLHAT: Secondary Endpoints
Chlorthalidone
JAMA 2002;288:2981-2997
Amlodipine
Heart Failure
RR =
p <
Chlorthalidone
Amlodipine
Chlorthalidone vs Amlodipine
All Cause Mortality
RR =
p =
ALLHAT: Secondary Endpoints
Chlorthalidone
JAMA 2002;288:2981-2997
Lisinopril
Heart Failure
RR =
p <
Chlorthalidone vs Lisinopril
Chlorthalidone
Lisinopril
Chlorthalidone
Lisinopril
Stroke
RR =
p =
ALLHAT: Summary
Prespecified primary endpoint of fatal CHD or nonfatal MI did not differ between initial use of the diuretic chlorthalidone vs initial use of the ACE inhibitor lisinopril or the calcium antagonist amlodipine for the treatment of hypertension
Secondary outcome of heart failure was lower among patients treated with chlorthalidone vs lisinopril or amlodipine
Each of the 3 drugs reduced blood pressure from baseline, although chlorthalidone use was associated with larger SBP reductions vs lisinopril or amlodipine
Increased risk of heart failure in lisinopril arm unexpected and in contrast to the benefits of ACE inhibitors observed in other tri